"exciting potential new partnerships on the horizon"

"I strongly believe in the Company's prospects and business opportunities that lie ahead," stated Silverman


Purchase Collectively More Than 11 Million Shares of the Company's Stock at Market Price

http://finance.yahoo.com/news/veriteqs-chairman-ceo-scott-r-123000340.html


ABOUT
VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.

"exciting potential new partnerships on the horizon"

"I strongly believe in the Company's prospects and business opportunities that lie ahead," stated Silverman


Purchase Collectively More Than 11 Million Shares of the Company's Stock at Market Price


http://finance.yahoo.com/news/veriteqs-chairman-ceo-scott-r-123000340.html

ABOUT
VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.

"exciting potential new partnerships on the horizon"

"I strongly believe in the Company's prospects and business opportunities that lie ahead," stated Silverman


Purchase Collectively More Than 11 Million Shares of the Company's Stock at Market Price

http://finance.yahoo.com/news/veriteqs-chairman-ceo-scott-r-123000340.html


ABOUT
VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.

Cant deny the interest though this past month. Even b4 the R/S this stock did not see this kind of volume.

Exactly...Its an interesting one for sure trading on the OTC. Lets see if patience pays!

"exciting potential new partnerships on the horizon"




http://finance.yahoo.com/news/veriteqs-chairman-ceo-scott-r-123000340.html

"Company's prospects and business opportunities that lie ahead"



http://finance.yahoo.com/news/veriteqs-chairman-ceo-scott-r-123000340.html

Valid reason...Hostile takeover! Proven product....which company are you referring too maybe we could compare apples to apples or .... lemons?


VTEQ - FDA CLEARED!

.....

Excellent point - I always have my sell orders in after buy! I agree to have everyone on board!


Looking mighty fine. Earlier i saw a lot of MM's moving around .03 range as well. Would be an AWESOME launch pad range!

BKMM MM has been a huge axe since pennyland. He is now on the BID first time i have seen him buying in months.

Time turn it around!

VTEQ ~ VeriTeQ Files Its 10-K and Announces 2014 Highlights

VTEQ ~ "FDA CLEARED" - Amount Beneficially Owned: 1,679,787
(b)Percent of Class: 5.5% based on 30,802,114 shares of common stock outstanding as of March 31, 2015

DELRAY BEACH, Fla., April 13, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has expanded its intellectual property portfolio with a patent filing in Brazil for its high-temperature Q Inside Safety Technology micro-transponder.

http://finance.yahoo.com/news/veriteq-corporation-expands-intellectual-property-123000685.html


VeriTeQ would exclusively license its intellectual property, safety data test and FDA file reference, and business opportunities related to its Q Inside Safety Technology for the breast implant market to EL, and EL would pay an upfront license fee of $1.75 million. EL would also have a 24-month option to purchase VeriTeQ's Q Inside Safety Technology business for the breast implant market for $10 million


http://finance.yahoo.com/news/veriteq-corporation-executes-term-sheet-133000890.html



February 5, 2015 10:25 AM
GlobeNewswire

DELRAY BEACH, Fla., Feb. 5, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation ("VeriTeQ" or "Company") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, today commented on this morning's Today Show segment entitled "Company implants microchips in employees." The segment represents that RF (radio frequency) access applications are new or first of a kind. This is not accurate. Specifically, years ago, VeriTeQ's predecessors, VeriChip Corporation/Applied Digital Solutions, received FDA clearance in 2004 to use an implantable RF micro-transponder to access medical records in an emergency or clinical application. One of VeriChip's other applications was building / office access


http://finance.yahoo.com/news/veriteq-corporation-comments-mornings-today-152522604.html

CHART

VTEQ ~ Amount Beneficially Owned: 1,679,787

(b)Percent of Class: 5.5% based on 30,802,114 shares of common stock outstanding as of March 31, 2015

DELRAY BEACH, Fla., April 13, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has expanded its intellectual property portfolio with a patent filing in Brazil for its high-temperature Q Inside Safety Technology micro-transponder.

http://finance.yahoo.com/news/veriteq-corporation-expands-intellectual-property-123000685.html


VeriTeQ would exclusively license its intellectual property, safety data test and FDA file reference, and business opportunities related to its Q Inside Safety Technology for the breast implant market to EL, and EL would pay an upfront license fee of $1.75 million. EL would also have a 24-month option to purchase VeriTeQ's Q Inside Safety Technology business for the breast implant market for $10 million


http://finance.yahoo.com/news/veriteq-corporation-executes-term-sheet-133000890.html



CHART

VTEQ ~ Amount Beneficially Owned: 1,679,787

(b)Percent of Class: 5.5% based on 30,802,114 shares of common stock outstanding as of March 31, 2015

DELRAY BEACH, Fla., April 13, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has expanded its intellectual property portfolio with a patent filing in Brazil for its high-temperature Q Inside Safety Technology micro-transponder.

http://finance.yahoo.com/news/veriteq-corporation-expands-intellectual-property-123000685.html


VeriTeQ would exclusively license its intellectual property, safety data test and FDA file reference, and business opportunities related to its Q Inside Safety Technology for the breast implant market to EL, and EL would pay an upfront license fee of $1.75 million. EL would also have a 24-month option to purchase VeriTeQ's Q Inside Safety Technology business for the breast implant market for $10 million


http://finance.yahoo.com/news/veriteq-corporation-executes-term-sheet-133000890.html



CHART

VTEQ ~ Amount Beneficially Owned: 1,679,787

(b)Percent of Class: 5.5% based on 30,802,114 shares of common stock outstanding as of March 31, 2015

DELRAY BEACH, Fla., April 13, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has expanded its intellectual property portfolio with a patent filing in Brazil for its high-temperature Q Inside Safety Technology micro-transponder.

http://finance.yahoo.com/news/veriteq-corporation-expands-intellectual-property-123000685.html


VeriTeQ would exclusively license its intellectual property, safety data test and FDA file reference, and business opportunities related to its Q Inside Safety Technology for the breast implant market to EL, and EL would pay an upfront license fee of $1.75 million. EL would also have a 24-month option to purchase VeriTeQ's Q Inside Safety Technology business for the breast implant market for $10 million


http://finance.yahoo.com/news/veriteq-corporation-executes-term-sheet-133000890.html



CHART

Amount Beneficially Owned: 1,679,787

(b)Percent of Class: 5.5% based on 30,802,114 shares of common stock outstanding as of March 31, 2015




http://ih.advfn.com/p.php?pid=nmona&article=66209383

VeriTeQ Corporation Expands Intellectual Property Portfolio With Patent Filing in Brazil

VeriTeQ Seeks Patent Protection for Its High-Temperature Q Inside Safety Technology Micro-Transponder in Brazil Due to Significant Breast Implant Market Opportunity

DELRAY BEACH, Fla., April 13, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has expanded its intellectual property portfolio with a patent filing in Brazil for its high-temperature Q Inside Safety Technology micro-transponder.

Q Inside Safety Technology™ acts as an electronic serial number within implanted medical devices, and enables physicians and patients to access a secure, online database to retrieve implant-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the device manufacturer.

Q Inside Safety Technology is currently being used within Establishment Labs S.A. ("EL") Motiva Implant Matrix® breast implants. EL markets its CE marked breast implants throughout Europe, the United Kingdom, Latin America and Asia. According to the International Society of Aesthetic Plastic Surgeons, there were over 500,000 breast procedures performed in Brazil in 2013.

During the manufacturing process, breast implants are sterilized at high heat. The patent filing is intended to protect the high-temperature Q Inside Safety Technology transponders that can withstand high-temperature shocks and can maintain their physical and electrical characteristics following high-temperature exposure.

"Brazil is the second largest market in the world for breast procedures, so we believe it is important that we protect the advances we have made to Q Inside Safety Technology as the use of our technology grows throughout that country and elsewhere," stated Scott R. Silverman, Chairman and CEO of VeriTe

VeriTeQ Corporation Expands Intellectual Property Portfolio With Patent Filing in Brazil

VeriTeQ Seeks Patent Protection for Its High-Temperature Q Inside Safety Technology Micro-Transponder in Brazil Due to Significant Breast Implant Market Opportunity

DELRAY BEACH, Fla., April 13, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has expanded its intellectual property portfolio with a patent filing in Brazil for its high-temperature Q Inside Safety Technology micro-transponder.

Q Inside Safety Technology™ acts as an electronic serial number within implanted medical devices, and enables physicians and patients to access a secure, online database to retrieve implant-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the device manufacturer.
Q Inside Safety Technology is currently being used within Establishment Labs S.A. ("EL") Motiva Implant Matrix® breast implants. EL markets its CE marked breast implants throughout Europe, the United Kingdom, Latin America and Asia. According to the International Society of Aesthetic Plastic Surgeons, there were over 500,000 breast procedures performed in Brazil in 2013.

During the manufacturing process, breast implants are sterilized at high heat. The patent filing is intended to protect the high-temperature Q Inside Safety Technology transponders that can withstand high-temperature shocks and can maintain their physical and electrical characteristics following high-temperature exposure.

"Brazil is the second largest market in the world for breast procedures, so we believe it is important that we protect the advances we have made to Q Inside Safety Technology as the use of our technology grows throughout that country and elsewhere," stated Scott R. Silverman, Chairman and CEO of VeriTe

$VTEQ ~ EL would also have a 24-month option to purchase VeriTeQ's Q Inside Safety Technology business for the breast implant market for $10 million, minus the license fee.

Said Scott R. Silverman, Chairman and CEO of VeriTeQ. "Not only will EL deliver cash upfront to us, but also we believe this agreement will ultimately result in increased sales of our products...."
The parties agreed to work towards finalizing more formal documentation/contracts within 90 days


READ MORE:
http://finance.yahoo.com/news/veriteq-corporation-executes-term-sheet-133000890.html

$VTEQ ~ EL would also have a 24-month option to purchase VeriTeQ's Q Inside Safety Technology business for the breast implant market for $10 million, minus the license fee.

Said Scott R. Silverman, Chairman and CEO of VeriTeQ. "Not only will EL deliver cash upfront to us, but also we believe this agreement will ultimately result in increased sales of our products...."
The parties agreed to work towards finalizing more formal documentation/contracts within 90 days


READ MORE:
http://finance.yahoo.com/news/veriteq-corporation-executes-term-sheet-133000890.html

$VTEQ ~ EL would also have a 24-month option to purchase VeriTeQ's Q Inside Safety Technology business for the breast implant market for $10 million, minus the license fee.

Said Scott R. Silverman, Chairman and CEO of VeriTeQ. "Not only will EL deliver cash upfront to us, but also we believe this agreement will ultimately result in increased sales of our products...."


The parties agreed to work towards finalizing more formal documentation/contracts within 90 days


READ MORE (FEB -PR):
http://finance.yahoo.com/news/veriteq-corporation-executes-term-sheet-133000890.html


About VeriTeQ

VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. [color=green]VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care[/color]. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.


CHART:

MUST READ DD >> VeriTeQ Corporation (VTEQ), the Food And Drug Administration (FDA) has approved VeriTeQ’s (VTEQ) cutting edge technologies. The company is now engaged in there commercial launch generating revenues that are projected to grow at explosive rates, quarter over quarter, year over year!

ORIGINAL POST:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110388365


Highlights:

-VeriTeQ (VTEQ) offers the world’s first FDA cleared RFID microchip technology that can be used to identify implantable medical devices,

-The FDA has mandated that starting September 2014 a national system be in place to identify medical devices during their distribution and use.

-EL would also have a 24-month option to purchase VeriTeQ's Q Inside Safety Technology business for the breast implant market for $10 million, minus the license fee.

Said Scott R. Silverman, Chairman and CEO of VeriTeQ. "Not only will EL deliver cash upfront to us, but also we believe this agreement will ultimately result in increased sales of our products...."



-What this all means is that VeriTeQ will have the government mandating that other companies use their product in order to be in FDA compliance. How great is that, estimates are that VeriTeQ will generate $239 million in future revenues thanks to it’s leading first-to-market world’s first FDA cleared RFIDmicrochip technology!

-VeriTeQ’s (VTEQ) FDA cleared dosimeter technologies for use in radiation therapy treatment.

- VeriTeQ’s “One Dose” external sensor is the only wireless pre-calbrated sensor on the market that can instantly provide measurement of radiation of dose delivered at skin level. VeriTeQ’s internal FDA cleared sensor is the only one on the market that confirms radiation dose directly to the tumor. The FDA has approved it for use in prostrate and breast cancer radiotherapy. Revenues generated from VeriTeQ’s FDA cleared dosimeter technologies for use in radiation therapy treatment are projected to be larger than those for it’s RFID microchip technology.



Yet VeriTeQ’s (VTEQ) share price is trading currently at historic lows in the sub penny range, under the radar! Now is the time to buy VeriTeQ (VTEQ), at this level huge percentage gains are not only possible but very likely as huge revenues flow in and grow at explosive rates, quarter over quarter, year over year!

Lets examine VeriTeQ’s (VTEQ) FDA approved innovative technologies and then be astounded that this stock is trading sub-penny, it should and likely will be trading in the multiple dollar range in the near future as the market catches up!

VeriTeQ’s (VTEQ) FDA cleared, radio frequency identification (RFID) solutions

VeriTeQ’s (VTEQ) FDA cleared, radio frequency identification (RFID) solutions identify implantable medical devices. This acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients access to secure online databases to retrieve device-specific data from the medical device manufacturer. VeriTeQ offers the world’s first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care.

The [B]FDA has mandated that starting September 2014 a national system be in place to identify medical devices during their distribution and use. This unique identification system known as (UDI) will be used for multiple functions including in the event of adverse events or recalls to facilitate the identification of the implanted device, more efficiently target recalls and reduce the chance that patients receive devices that have been identified as problematic.

What this all means is that VeriTeQ will have the government mandating that other companies use their product in order to be in FDA compliance. How great is that, estimates are that VeriTeQ will generate $239 million in future revenues thanks to it’s leading first-to-marketworld’s first FDA cleared RFID microchip technology!

To summarize, VeriTeQ will sell RFID microchips that will be inserted into breast implants, artificial joints etc that can then be scanned by medical personnel using VeriTeQ’s hand held scanner. VeriTech generates revenues on the RFID microchips and their hand held scanner!

According to the International Society of Aesthetic Plastic Surgery, the number of breast augmentation procedures performed worldwide in 2011 exceeded 1.2 million.

VeriTeQ’s (VTEQ) FDA cleared dosimeter technologies for use in radiation therapy treatment.

VeriTeQ’s dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. Accurate and timely data on radiation doses delivered to patients is increasingly recognized as critical to patient safety, quality assurance and risk management. Instances of radiation overdose involving hundreds of patients have occurred at prominent hospitals across the country. VeriTeQ’s dosimeter technologies provide radiation oncologists a valuable tool to help ensure patient safety and improve the overall quality of care.

VeriTeQ’s “One Dose” external sensor is the only wireless pre-calbrated sensor on the market that can instantly provide measurement of radiation of dose delivered at skin level.

VeriTeQ’s internal FDA cleared sensor is the only one on the market that confirms radiation dose directly to the tumor. The FDA has approved it for use in prostrate and breast cancer radiotherapy. VeriTeQ future goals could include it being FDA approved for colorectal ,pancreatic and lung tumor types.

The revenue potential here is massive and could dwarf the huge revenues projected from VeriTeQ’s RFID microchip technology. VeriTeQ’s initial target market is the over 1 million patients receiving external beam radiation therapy in the United States alone and potential revenues from internal radiation measurement and new FDA treatment pathways.

Some of the most recent exciting developments for VeriTeQ (VTEQ)

(This is an exciting growing company with a product that has been mandated for use by the FDA, innovative, transparent and now insanely undervalued trading in the sub penny range. Now is the time to buy with blue skies ahead!))

November 24th 2014: VeriTeQ (VTEQ)announced that in conjunction with its customer Establishment Labs it will initiate development of a pressure-sensing microtransponder to be used in tissue expanders for breast reconstruction and tissue expansion.

November 5th 2014: VeriTeQ (VTEQ) announced new financing with New York investment firm Magna for up to $450,000.

October 15th 2014: VeriTeQ (VTEQ) announced that the Company and its breast implant customer, Establishment Labs planned to host a physician conference in Salzburg, Austria.

October 9th 2014: VeriTeQ (VTEQ) announced today that it has entered an agreement providing an exclusive license of multiple patents from North Carolina State University (“NCSU”). VeriTeQ will license 24 patents, which are the foundation for its FDA cleared Q Inside SmartMarker and OneDose products for radiation dosimetry.

September 29th 2014: VeriTeQ (VTEQ) announced today that it has received an order for 100 units of its new Q Inside readers for breast implants

September 18th 2014: VeriTeQ (VTEQ) announced today that it has unveiled two new readers used to identify VeriTeQ’s Q Inside Safety Technology(TM) within implantable medical devices: the Q Inside Reader + and the Q Inside Reader XR +. The new readers are being launched based on demand from the breast implant industry.

September 16th 2014: VeriTeQ (VTEQ) announced today that more than 1,000 women worldwide have now received Motiva Implant Matrix® breast implants with VeriTeQ’s Q Inside Safety Technology™. Motiva Implant Matrix® breast implants, manufactured by Establishment Labs S.A. (“EL”), featuring VeriTeQ’s Q Inside Safety Technology™ can be safely and accurately identified from outside of the body in a physician’s office

August 26th 2014: VeriTeQ (VTEQ) announced today that it will host a conference call on Wednesday, September 3, 2014, at 10 a.m. ET, to update investors on the business and other recent events.

July 9th 2014: VeriTeQ (VTEQ) announced today that it received an order for 10,200 Q Inside Safety Technology™ radio frequency identification microtransponders from breast implant customer Establishment Labs (“EL”). EL will use Q Inside Safety Technology microtransponders for the continued commercialization of its Motiva Implant Matrix® breast implants throughout Europe.

More interesting information on why now is the time to buy VeriTeQ (VTEQ)

VeriTeQ’s Chairman and CEO, Scott R. Silverman “Now that the commercial launch of our products is underway and we are becoming more active in the capital

markets with a goal of a future up-listing”

Flying so low under the radar, It only went public in July 2013 and is completely oversold, trading at historic lows with the share price now incredibly in the sub-penny range.

In February 2014 Zacks Investment Research (“Zacks”) initiated coverage of the Company with an outperform rating, meaning that they anticipated it will outperform

other stocks in it’s sector, now that is essentially a BUY rating!

VeriTeQ is currently working with breast implant manufacturer Establishment Labs, S.A., which markets its Motiva Implant Matrix® breast implants with VeriTeQ’s Q

Inside Safety Technology in the European Union

Establishment Labs has begun the commercial launch of its Motiva Implant Matrix® breast implants with VeriTeQ’s Q Inside Safety Technology in the European Union.

EL’s Motiva Implant Matrix Ergonomix, VelvetSurface PLUS, and SilkSurface PLUS, all with VeriTeQ’s Q Inside Safety Technology, have received CE Mark approval, which enables Establishment Labs to market its Motiva breast implants to patients in 28 countries in the European Union and fast track regulatory approvals in many countries in South America, Middle East and Asia.

VeriTeQ looks to have a break out year in 2015: Core Technology: implantable radio frequency (RF) microchip technology with over 100 Patents, Patent Pendings, and Licensed Applications

Michael Krawitz its Chief Legal and Financial Officer. Mr. Krawitz is a skilled executive with extensive capital markets experience who holds a a juris doctorate from Harvard Law School. Krawitz stated, “VeriTeQ captured my interest with OneDose and related products that allow radiation oncologists to more accurately deliver radiation therapy. It’s a

great example of what VeriTeQ does with all of its products — using technology to give doctors, nurses and patients more accurate information, leading to better

treatment and fewer mistakes. I’m proud to be a part of that. From a business perspective, we believe our products result in better treatment and fewer mistakes,

thereby reducing liability and offering a competitive advantage for hospitals and doctors. I am excited to work again with Scott and our team on this early opportunity to

grow VeriTeQ and participate in its long-term success.”



This write up of VeriTeQ Corporation (VTEQ) contains information from multiple sources including:

VeriTeQ’s (VTEQ) website

http://www.veriteqcorp.com/

Official Press Releases

http://finance.yahoo.com/q/p?s=VTEQ+Press+Releases

A Seeking Alpha article

http://seekingalpha.com/article/1939671-new-mandate-will-help-sell-veriteqs-fda-approved-microchip

Zach’s Investment Research

http://scr.zacks.com/files/doc_coverage/Med-Tech%20-%20Brian%20Marckx/VTEQ/February%2012%202014_VTEQ_Marckx.pdf




http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110388365



CHART:

MUST READ DD >> VeriTeQ Corporation (VTEQ), the Food And Drug Administration (FDA) has approved VeriTeQ’s (VTEQ) cutting edge technologies. The company is now engaged in there commercial launch generating revenues that are projected to grow at explosive rates, quarter over quarter, year over year!

ORIGINAL POST:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110388365


Highlights:

-VeriTeQ (VTEQ) offers the world’s first FDA cleared RFID microchip technology that can be used to identify implantable medical devices,

-The FDA has mandated that starting September 2014 a national system be in place to identify medical devices during their distribution and use.

-EL would also have a 24-month option to purchase VeriTeQ's Q Inside Safety Technology business for the breast implant market for $10 million, minus the license fee.

Said Scott R. Silverman, Chairman and CEO of VeriTeQ. "Not only will EL deliver cash upfront to us, but also we believe this agreement will ultimately result in increased sales of our products...."



-What this all means is that VeriTeQ will have the government mandating that other companies use their product in order to be in FDA compliance. How great is that, estimates are that VeriTeQ will generate $239 million in future revenues thanks to it’s leading first-to-market world’s first FDA cleared RFIDmicrochip technology!

-VeriTeQ’s (VTEQ) FDA cleared dosimeter technologies for use in radiation therapy treatment.

- VeriTeQ’s “One Dose” external sensor is the only wireless pre-calbrated sensor on the market that can instantly provide measurement of radiation of dose delivered at skin level. VeriTeQ’s internal FDA cleared sensor is the only one on the market that confirms radiation dose directly to the tumor. The FDA has approved it for use in prostrate and breast cancer radiotherapy. Revenues generated from VeriTeQ’s FDA cleared dosimeter technologies for use in radiation therapy treatment are projected to be larger than those for it’s RFID microchip technology.



Yet VeriTeQ’s (VTEQ) share price is trading currently at historic lows in the sub penny range, under the radar! Now is the time to buy VeriTeQ (VTEQ), at this level huge percentage gains are not only possible but very likely as huge revenues flow in and grow at explosive rates, quarter over quarter, year over year!

Lets examine VeriTeQ’s (VTEQ) FDA approved innovative technologies and then be astounded that this stock is trading sub-penny, it should and likely will be trading in the multiple dollar range in the near future as the market catches up!

VeriTeQ’s (VTEQ) FDA cleared, radio frequency identification (RFID) solutions

VeriTeQ’s (VTEQ) FDA cleared, radio frequency identification (RFID) solutions identify implantable medical devices. This acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients access to secure online databases to retrieve device-specific data from the medical device manufacturer. VeriTeQ offers the world’s first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care.

The [B]FDA has mandated that starting September 2014 a national system be in place to identify medical devices during their distribution and use. This unique identification system known as (UDI) will be used for multiple functions including in the event of adverse events or recalls to facilitate the identification of the implanted device, more efficiently target recalls and reduce the chance that patients receive devices that have been identified as problematic.

What this all means is that VeriTeQ will have the government mandating that other companies use their product in order to be in FDA compliance. How great is that, estimates are that VeriTeQ will generate $239 million in future revenues thanks to it’s leading first-to-marketworld’s first FDA cleared RFID microchip technology!

To summarize, VeriTeQ will sell RFID microchips that will be inserted into breast implants, artificial joints etc that can then be scanned by medical personnel using VeriTeQ’s hand held scanner. VeriTech generates revenues on the RFID microchips and their hand held scanner!

According to the International Society of Aesthetic Plastic Surgery, the number of breast augmentation procedures performed worldwide in 2011 exceeded 1.2 million.

VeriTeQ’s (VTEQ) FDA cleared dosimeter technologies for use in radiation therapy treatment.

VeriTeQ’s dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. Accurate and timely data on radiation doses delivered to patients is increasingly recognized as critical to patient safety, quality assurance and risk management. Instances of radiation overdose involving hundreds of patients have occurred at prominent hospitals across the country. VeriTeQ’s dosimeter technologies provide radiation oncologists a valuable tool to help ensure patient safety and improve the overall quality of care.

VeriTeQ’s “One Dose” external sensor is the only wireless pre-calbrated sensor on the market that can instantly provide measurement of radiation of dose delivered at skin level.

VeriTeQ’s internal FDA cleared sensor is the only one on the market that confirms radiation dose directly to the tumor. The FDA has approved it for use in prostrate and breast cancer radiotherapy. VeriTeQ future goals could include it being FDA approved for colorectal ,pancreatic and lung tumor types.

The revenue potential here is massive and could dwarf the huge revenues projected from VeriTeQ’s RFID microchip technology. VeriTeQ’s initial target market is the over 1 million patients receiving external beam radiation therapy in the United States alone and potential revenues from internal radiation measurement and new FDA treatment pathways.

Some of the most recent exciting developments for VeriTeQ (VTEQ)

(This is an exciting growing company with a product that has been mandated for use by the FDA, innovative, transparent and now insanely undervalued trading in the sub penny range. Now is the time to buy with blue skies ahead!))

November 24th 2014: VeriTeQ (VTEQ)announced that in conjunction with its customer Establishment Labs it will initiate development of a pressure-sensing microtransponder to be used in tissue expanders for breast reconstruction and tissue expansion.

November 5th 2014: VeriTeQ (VTEQ) announced new financing with New York investment firm Magna for up to $450,000.

October 15th 2014: VeriTeQ (VTEQ) announced that the Company and its breast implant customer, Establishment Labs planned to host a physician conference in Salzburg, Austria.

October 9th 2014: VeriTeQ (VTEQ) announced today that it has entered an agreement providing an exclusive license of multiple patents from North Carolina State University (“NCSU”). VeriTeQ will license 24 patents, which are the foundation for its FDA cleared Q Inside SmartMarker and OneDose products for radiation dosimetry.

September 29th 2014: VeriTeQ (VTEQ) announced today that it has received an order for 100 units of its new Q Inside readers for breast implants

September 18th 2014: VeriTeQ (VTEQ) announced today that it has unveiled two new readers used to identify VeriTeQ’s Q Inside Safety Technology(TM) within implantable medical devices: the Q Inside Reader + and the Q Inside Reader XR +. The new readers are being launched based on demand from the breast implant industry.

September 16th 2014: VeriTeQ (VTEQ) announced today that more than 1,000 women worldwide have now received Motiva Implant Matrix® breast implants with VeriTeQ’s Q Inside Safety Technology™. Motiva Implant Matrix® breast implants, manufactured by Establishment Labs S.A. (“EL”), featuring VeriTeQ’s Q Inside Safety Technology™ can be safely and accurately identified from outside of the body in a physician’s office

August 26th 2014: VeriTeQ (VTEQ) announced today that it will host a conference call on Wednesday, September 3, 2014, at 10 a.m. ET, to update investors on the business and other recent events.

July 9th 2014: VeriTeQ (VTEQ) announced today that it received an order for 10,200 Q Inside Safety Technology™ radio frequency identification microtransponders from breast implant customer Establishment Labs (“EL”). EL will use Q Inside Safety Technology microtransponders for the continued commercialization of its Motiva Implant Matrix® breast implants throughout Europe.

More interesting information on why now is the time to buy VeriTeQ (VTEQ)

VeriTeQ’s Chairman and CEO, Scott R. Silverman “Now that the commercial launch of our products is underway and we are becoming more active in the capital

markets with a goal of a future up-listing”

Flying so low under the radar, It only went public in July 2013 and is completely oversold, trading at historic lows with the share price now incredibly in the sub-penny range.

In February 2014 Zacks Investment Research (“Zacks”) initiated coverage of the Company with an outperform rating, meaning that they anticipated it will outperform

other stocks in it’s sector, now that is essentially a BUY rating!

VeriTeQ is currently working with breast implant manufacturer Establishment Labs, S.A., which markets its Motiva Implant Matrix® breast implants with VeriTeQ’s Q

Inside Safety Technology in the European Union

Establishment Labs has begun the commercial launch of its Motiva Implant Matrix® breast implants with VeriTeQ’s Q Inside Safety Technology in the European Union.

EL’s Motiva Implant Matrix Ergonomix, VelvetSurface PLUS, and SilkSurface PLUS, all with VeriTeQ’s Q Inside Safety Technology, have received CE Mark approval, which enables Establishment Labs to market its Motiva breast implants to patients in 28 countries in the European Union and fast track regulatory approvals in many countries in South America, Middle East and Asia.

VeriTeQ looks to have a break out year in 2015: Core Technology: implantable radio frequency (RF) microchip technology with over 100 Patents, Patent Pendings, and Licensed Applications

Michael Krawitz its Chief Legal and Financial Officer. Mr. Krawitz is a skilled executive with extensive capital markets experience who holds a a juris doctorate from Harvard Law School. Krawitz stated, “VeriTeQ captured my interest with OneDose and related products that allow radiation oncologists to more accurately deliver radiation therapy. It’s a

great example of what VeriTeQ does with all of its products — using technology to give doctors, nurses and patients more accurate information, leading to better

treatment and fewer mistakes. I’m proud to be a part of that. From a business perspective, we believe our products result in better treatment and fewer mistakes,

thereby reducing liability and offering a competitive advantage for hospitals and doctors. I am excited to work again with Scott and our team on this early opportunity to

grow VeriTeQ and participate in its long-term success.”



This write up of VeriTeQ Corporation (VTEQ) contains information from multiple sources including:

VeriTeQ’s (VTEQ) website

http://www.veriteqcorp.com/

Official Press Releases

http://finance.yahoo.com/q/p?s=VTEQ+Press+Releases

A Seeking Alpha article

http://seekingalpha.com/article/1939671-new-mandate-will-help-sell-veriteqs-fda-approved-microchip

Zach’s Investment Research

http://scr.zacks.com/files/doc_coverage/Med-Tech%20-%20Brian%20Marckx/VTEQ/February%2012%202014_VTEQ_Marckx.pdf




http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110388365



CHART:

The "Q" is just in their name and product. No filing for bankruptcy or BR play. Up and coming company and FDA cleared product!!!

DELRAY BEACH, Fla., March 12, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, and Establishment Labs, S.A. ("EL") announced today that The Hospital Group, the largest provider of cosmetic surgery in the United Kingdom ("UK"), now offers EL's Motiva Implant Matrix(R) breast implants with VeriTeQ's Q Inside Safety Technology(TM) to patients choosing to undergo breast augmentation. The Hospital Group operates a network of more than 20 clinics around the UK and Ireland.

Q Inside Safety Technology(TM) is an FDA cleared micro-transponder technology that acts as an electronic serial number enabling physicians and patients to access a secure, online database to retrieve implant-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the device manufacturer. Q Inside Safety Technology(TM) may also provide an extra level of protection to the patient in the event of a recall or other safety event.

$VTEQ ~ EL would also have a 24-month option to purchase VeriTeQ's Q Inside Safety Technology business for the breast implant market for $10 million, minus the license fee.

Said Scott R. Silverman, Chairman and CEO of VeriTeQ. "Not only will EL deliver cash upfront to us, but also we believe this agreement will ultimately result in increased sales of our products...."


The parties agreed to work towards finalizing more formal documentation/contracts within 90 days


READ MORE (FEB -PR):
http://finance.yahoo.com/news/veriteq-corporation-executes-term-sheet-133000890.html


About VeriTeQ

VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. [color=green]VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care[/color]. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.


CHART:

$VTEQ ~ EL would also have a 24-month option to purchase VeriTeQ's Q Inside Safety Technology business for the breast implant market for $10 million, minus the license fee.

Said Scott R. Silverman, Chairman and CEO of VeriTeQ. "Not only will EL deliver cash upfront to us, but also we believe this agreement will ultimately result in increased sales of our products...."


The parties agreed to work towards finalizing more formal documentation/contracts within 90 days


READ MORE (FEB -PR):
http://finance.yahoo.com/news/veriteq-corporation-executes-term-sheet-133000890.html


About VeriTeQ

VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. [color=green]VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care[/color]. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.


CHART:

$VTEQ ~ EL would also have a 24-month option to purchase VeriTeQ's Q Inside Safety Technology business for the breast implant market for $10 million, minus the license fee.

Said Scott R. Silverman, Chairman and CEO of VeriTeQ. "Not only will EL deliver cash upfront to us, but also we believe this agreement will ultimately result in increased sales of our products...."


The parties agreed to work towards finalizing more formal documentation/contracts within 90 days


READ MORE (FEB -PR):
http://finance.yahoo.com/news/veriteq-corporation-executes-term-sheet-133000890.html


About VeriTeQ

VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. [color=green]VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care[/color]. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.


CHART:

$VTEQ ~ EL would also have a 24-month option to purchase VeriTeQ's Q Inside Safety Technology business for the breast implant market for $10 million, minus the license fee.

Said Scott R. Silverman, Chairman and CEO of VeriTeQ. "Not only will EL deliver cash upfront to us, but also we believe this agreement will ultimately result in increased sales of our products...."


The parties agreed to work towards finalizing more formal documentation/contracts within 90 days


READ MORE (FEB -PR):
http://finance.yahoo.com/news/veriteq-corporation-executes-term-sheet-133000890.html


About VeriTeQ

VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.


CHART:

The parties agreed to work towards finalizing more formal documentation/contracts within 90 days. --From PR in Feb. Valid reason for the late filing possibly working out details of the deal....Also a rise in the PPS could mean the deal maybe juicer then expected. All speculation until the next PR!



A couple reason | Feb. 12, 2015 (GLOBE NEWSWIRE0):
EL would also have a 24-month option to purchase VeriTeQ's Q Inside Safety Technology business for the breast implant market for $10 million, minus the license fee.

Said Scott R. Silverman, Chairman and CEO of VeriTeQ. "Not only will EL deliver cash upfront to us, but also we believe this agreement will ultimately result in increased sales of our products...."


The parties agreed to work towards finalizing more formal documentation/contracts within 90 days


READ MORE:
http://finance.yahoo.com/news/veriteq-corporation-executes-term-sheet-133000890.html

This is the reason i bet on we are seeing a rise in the PP$. Very interesting read!!!

VeriTeQ Corporation (OTC Markets: VTEQD) ("VeriTeQ"), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that that it has executed a term sheet with Establishment Labs, S.A., ("EL"). Under the proposed agreement, VeriTeQ would exclusively license its intellectual property, safety data test and FDA file reference, and business opportunities related to its Q Inside Safety Technology for the breast implant market to EL, and EL would pay an upfront license fee of $1.75 million. EL would also have a 24-month option to purchase VeriTeQ's Q Inside Safety Technology business for the breast implant market for $10 million, minus the license fee. VeriTeQ expects to continue to operate its business for the breast implant markets as well as other proprietary applications for its Q Inside Safety Technology.

The parties also intend to jointly develop a pressure-sensing radio frequency identification ("RFID") product to detect pressure thresholds in breast implants and other medical devices.

"Our partnership with Establishment Labs is very strong, and we see many benefits from granting this exclusive license for the breast implant market to EL," said Scott R. Silverman, Chairman and CEO of VeriTeQ. "Not only will EL deliver cash upfront to us, but also we believe this agreement will ultimately result in increased sales of our products, both to EL and other manufacturers of breast implants, which is advantageous to both companies."

The parties agreed to work towards finalizing more formal documentation/contracts within 90 days.


http://finance.yahoo.com/news/veriteq-corporation-executes-term-sheet-133000890.html

Looking great! Iam really starting to wonder if this has any correlation to the late filing!!

Looks good. Noticed volume picked up on the day of and before of the late filing notice. Upto 70% swings on decent volume... Wondering whats going on behind the scenes.



Lik'n the last 2 candles on the daily as well. Watch'n 2 key MM's closely next couple of days

Two 1.09 million share trades went in after hours @ double 0 32 & 33.

This is a make it or break it range. Last time VTEQ traded around this level for a week or 2 and then hit the trips. HOPEFULLY history does not repeat itself in this case.

Securities Purchase Agreement effective March 20, 2015, 8% Convertible Redeemable Notes due March 19, 2016 and Collateralized Secured Promissory Note due March 19, 2016



VeriTeQ Corporation (the “Company”) entered into a securities purchase agreement (the “SPA”), dated March 19, 2015 and effective March 20, 2015, with an accredited investor (the “Buyer”). Pursuant to the terms of the SPA, the Company issued and sold to the Buyer two 8% convertible promissory notes in the amount of $25,000 each. The first note for $25,000 (the “8% Note”) was paid for by the Buyer on March 20, 2015 in cash, less $4,000 of transaction expenses, with net proceeds of $21,000 being used for general corporate purposes. The second note (“8% Second Note”) was paid for by the issuance of an offsetting $25,000 secured note issued to the Company by the Buyer, (the “8% Buyer Note”) which is to be paid in cash to the Company no later than November 19, 2015.



The 8% Note matures on March 19, 2016. It may be converted in whole or in part into the Company's common stock, at the option of the Buyer, at any time prior to the maturity date at a conversion price of 61% of the lowest closing price of the Company’s common stock for the 15 prior trading days, including the day upon which the conversion notice is received by the Company. However, the Buyer may not effect a conversion if such conversion, along with all other shares of Company common stock beneficially owned by the Buyer and its affiliates, would exceed 9.9% of the outstanding shares of the Company’s common stock.



During the first 180 days that the 8% Note is in effect, the Company may redeem the note by paying to the holder an amount equal to 150% of the face amount plus any accrued interest, after which time the note cannot be prepaid. Interest on any unpaid principal balance of the 8% Note shall be paid at the rate of 8% per annum. Interest on the 8% Note shall be paid by the Company in shares of its common stock (“Interest Shares”). The holder may, at any time, send in a notice of conversion to the Company for Interest Shares based on the formula provided above for principal conversions.



The 8% Second Note matures on March 19, 2016. The holder of the 8% Second Note is entitled, at its option, after the expiration of the requisite Rule 144 holding period and after full cash payment of the 8% Buyer Note, to convert all or any amount of the principal face amount of the 8% Second Note then outstanding into shares of the Company's common stock at a conversion price for each share of the Company’s common stock equal to 61% of the lowest closing price of the Company’s common stock for the 15 prior trading days, including the day upon which the conversion notice is received by the Company. The 8% Second Note may not be prepaid, except in certain circumstances described therein. Interest on any unpaid principal balance of the 8% Second Note shall be paid by the Company in Interest Shares. The holder may, at any time, send in a notice of conversion to the Company for Interest Shares based on the formula provided above for principal conversions.



The 8% Note and the 8% Second Note contain certain covenants and restrictions, including, among others, that, for so long as the notes are outstanding the Company will not dispose of certain assets and will maintain its listing on an over-the-counter market. Events of default under the note include, among others, failure to pay principal or interest on the note or comply with certain covenants under the note.



As discussed above, the Buyer issued to the Company the 8% Buyer Note, also referred to as the Collateralized Secured Promissory Back End Note, in the amount of $25,000, which matures on November 19, 2016, unless the Company does not meet the “current information requirements” required under Rule 144 of the Securities Act of 1933, as amended, in which case the Buyer may declare the 8% Second Note to be in default (as defined in that note) and cross cancel its payment obligations under the 8% Buyer Note against the Company’s payment obligations under the 8% Second Note. The 8% Buyer Note shall bear simple interest at the rate of 8%. The Buyer may, at its option, prepay the 8% Buyer Note at any time.








--------------------------------------------------------------------------------





The foregoing descriptions of the SPA, 8% Note, 8% Second Note and the 8% Buyer Note are summaries, and are qualified in their entirety by reference to such documents, which are attached hereto as Exhibit 10.1, Exhibit 10.2, Exhibit 10.3, and Exhibit 10.4, respectively, and are incorporated herein by reference.



12% Convertible Promissory Notes due March 17, 2016



On March 19, 2015, the Company issued and sold to Magna Equities II, LLC, an accredited investor (“Magna”), a convertible promissory note, bearing interest at 12% per annum in the aggregate principal amount of $77,500 (the “Magna Note”). In accordance with the terms of the Notes, the Company agreed to pay Magna’s expenses associated with the transaction in the amount of $2,500. As a result, the Company realized net proceeds from the sale of the Magna Note in the amount of $75,000, which is being used for general corporate purposes. Principal and interest on the Magna Note are due on the maturity date of March 17, 2016. In the event that principal and interest are not paid when due, the interest rate increases to 22% per annum.



The Magna Note can be prepaid, at a redemption premium of 50%, at any time prior to maturity. The Magna Note is convertible at a price per share equal to the lesser of (i) $0.015 or (ii) 60% of the average of the lowest three trading prices of the Company’s common stock during the 10 trading days prior to conversion. However, in no event shall the holder be entitled to convert any portion of the Magna Note if such conversion would result in beneficial ownership by the holder and its affiliates of more than 9.99% of the outstanding shares of the Company’s common stock. If, at any time when the Magna Note is outstanding, the Company issues or sells, or is deemed to have issued or sold, any shares of its common stock in connection with a subsequent placement for no consideration or for a consideration per share that is less than the conversion price on the date of issuance or based on a variable price formula (the “Alternative Variable Price Formula”) that is more favorable to the subsequent investor than the foregoing variable conversion price formula, then the conversion price of the Magna Note will be reduced to the amount of the consideration per share received for such issuance or the conversion price will be adjusted to match the Alternative Variable Price Formula.

A national register logging every breast implant operation carried out in England is to be established in an attempt to prevent a repeat of the scandal in which tens thousands of women received faulty implants, ministers have said.

The Government has accepted the majority of the recommendations of a review carried out by Sir Bruce Keogh, the NHS medical director, following the disclosure that the French firm Poly Implant Prothese (PIP) had been manufacturing implants using industrial grade silicone.

Almost 50,000 women in the UK and some 400,000 worldwide were affected by the scandal, which came to light two years ago when doctors found unexpectedly high numbers of women were suffering from ruptured implants.


http://www.theguardian.com/world/2013/dec/29/breast-implant-register-established-pip-scandal

More trades after the close. I wonder why they hold their orders till market close!

$VTEQ - , the Food And Drug Administration (FDA) has approved VeriTeQ’s (VTEQ) cutting edge technologies. The company is now engaged in there commercial launch generating revenues that are projected to grow at explosive rates, quarter over quarter, year over year!


DELRAY BEACH, Fla., Feb. 12, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation (OTC Markets: VTEQD) ("VeriTeQ"), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that that it has executed a term sheet with Establishment Labs, S.A., ("EL"). Under the proposed agreement, VeriTeQ would exclusively license its intellectual property, safety data test and FDA file reference, and business opportunities related to its Q Inside Safety Technology for the breast implant market to EL, and EL would pay an upfront license fee of $1.75 million. EL would also have a 24-month option to purchase VeriTeQ's Q Inside Safety Technology business for the breast implant market for $10 million, minus the license fee. VeriTeQ expects to continue to operate its business for the breast implant markets as well as other proprietary applications for its Q Inside Safety Technology.

http://www.biospace.com/News/veriteq-corporation-executes-term-sheet-for/364542

DELRAY BEACH, Fla., March 12, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, and Establishment Labs, S.A. ("EL") announced today that The Hospital Group, the largest provider of cosmetic surgery in the United Kingdom ("UK"), now offers EL's Motiva Implant Matrix(R) breast implants with VeriTeQ's Q Inside Safety Technology(TM) to patients choosing to undergo breast augmentation. The Hospital Group operates a network of more than 20 clinics around the UK and Ireland.


http://finance.yahoo.com/news/largest-provider-cosmetic-surgery-uk-143155051.html



Must Read DD Post:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110388365


SNAPSHOT





CHART

$VTEQ - , the Food And Drug Administration (FDA) has approved VeriTeQ’s (VTEQ) cutting edge technologies. The company is now engaged in there commercial launch generating revenues that are projected to grow at explosive rates, quarter over quarter, year over year!


DELRAY BEACH, Fla., Feb. 12, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation (OTC Markets: VTEQD) ("VeriTeQ"), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that that it has executed a term sheet with Establishment Labs, S.A., ("EL"). Under the proposed agreement, VeriTeQ would exclusively license its intellectual property, safety data test and FDA file reference, and business opportunities related to its Q Inside Safety Technology for the breast implant market to EL, and EL would pay an upfront license fee of $1.75 million. EL would also have a 24-month option to purchase VeriTeQ's Q Inside Safety Technology business for the breast implant market for $10 million, minus the license fee. VeriTeQ expects to continue to operate its business for the breast implant markets as well as other proprietary applications for its Q Inside Safety Technology.

http://www.biospace.com/News/veriteq-corporation-executes-term-sheet-for/364542

DELRAY BEACH, Fla., March 12, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, and Establishment Labs, S.A. ("EL") announced today that The Hospital Group, the largest provider of cosmetic surgery in the United Kingdom ("UK"), now offers EL's Motiva Implant Matrix(R) breast implants with VeriTeQ's Q Inside Safety Technology(TM) to patients choosing to undergo breast augmentation. The Hospital Group operates a network of more than 20 clinics around the UK and Ireland.


http://finance.yahoo.com/news/largest-provider-cosmetic-surgery-uk-143155051.html



Must Read DD Post:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110388365


SNAPSHOT





CHART

$VTEQ - , the Food And Drug Administration (FDA) has approved VeriTeQ’s (VTEQ) cutting edge technologies. The company is now engaged in there commercial launch generating revenues that are projected to grow at explosive rates, quarter over quarter, year over year!


DELRAY BEACH, Fla., Feb. 12, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation (OTC Markets: VTEQD) ("VeriTeQ"), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that that it has executed a term sheet with Establishment Labs, S.A., ("EL"). Under the proposed agreement, VeriTeQ would exclusively license its intellectual property, safety data test and FDA file reference, and business opportunities related to its Q Inside Safety Technology for the breast implant market to EL, and EL would pay an upfront license fee of $1.75 million. EL would also have a 24-month option to purchase VeriTeQ's Q Inside Safety Technology business for the breast implant market for $10 million, minus the license fee. VeriTeQ expects to continue to operate its business for the breast implant markets as well as other proprietary applications for its Q Inside Safety Technology.

http://www.biospace.com/News/veriteq-corporation-executes-term-sheet-for/364542

DELRAY BEACH, Fla., March 12, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, and Establishment Labs, S.A. ("EL") announced today that The Hospital Group, the largest provider of cosmetic surgery in the United Kingdom ("UK"), now offers EL's Motiva Implant Matrix(R) breast implants with VeriTeQ's Q Inside Safety Technology(TM) to patients choosing to undergo breast augmentation. The Hospital Group operates a network of more than 20 clinics around the UK and Ireland.


http://finance.yahoo.com/news/largest-provider-cosmetic-surgery-uk-143155051.html



Must Read DD Post:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110388365


SNAPSHOT





CHART